he rise of cancer immunotherapy such as immune checkpoint modulators, bispecific antibodies, T cell therapy and personalized cancer vaccines, instigated a wide range of unique preclinical and translational challenges. The demand for predictive and robust preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immune-oncology. Cambridge Healthtech Institute’s Sixth Annual Preclinical and Translational Immuno-Oncology conference is designed as a forum for ideas and opinions exchange to decrease the rate of clinical failures in immuno-oncology.
